EMA Authorised: Adasuve (loxapine) — Ferrer Internacional S.A.

View source ↗

Summary

The EMA authorised Adasuve (loxapine) by Ferrer Internacional S.A. for use in schizophrenia and bipolar disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Adasuve (loxapine)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia;Bipolar Disorder. MAH: Ferrer Internacional S.A.. Decision date: 01/10/2025